+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis



Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis



Journal of Translational Medicine 14(1): 216



Many investigators detected the simian polyomavirus SV40 footprints in human brain tumors and neurologic diseases and recently it has been indicated that SV40 seems to be associated with multiple sclerosis (MS) disease. Interestingly, SV40 interacts with human leukocyte antigen (HLA) class I molecules for cell entry. HLA class I antigens, in particular non-classical HLA-G molecules, characterized by an immune-regulatory function, are involved in MS disease, and the levels of these molecules are modified according with the disease status. We investigated in serum samples, from Italian patients affected by MS, other inflammatory diseases (OIND), non-inflammatory neurological diseases (NIND) and healthy subjects (HS), SV40-antibody and soluble sHLA-G and the association between SV40-prevalence and sHLA-G levels. ELISA tests were used for SV40-antibodies detection and sHLA-G quantitation in serum samples. The presence of SV40 antibodies was observed in 6 % of patients affected by MS (N = 4/63), 10 % of OIND (N = 8/77) and 15 % of NIND (N = 9/59), which is suggestive of a lower prevalence in respect to HS (22 %, N = 18/83). MS patients are characterized by higher sHLA-G serum levels (13.9 ± 0.9 ng/ml; mean ± St. Error) in comparison with OIND (6.7 ± 0.8 ng/ml), NIND (2.9 ± 0.4 ng/ml) and HS (2.6 ± 0.7 ng/ml) subjects. Interestingly, we observed an inverse correlation between SV40 antibody prevalence and sHLA-G serum levels in MS patients. The data obtained showed a low prevalence of SV40 antibodies in MS patients. These results seems to be due to a generalized status of inability to counteract SV40 infection via antibody production. In particular, we hypothesize that SV40 immune-inhibitory direct effect and the presence of high levels of the immune-inhibitory HLA-G molecules could co-operate in impairing B lymphocyte activation towards SV40 specific peptides.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058833883

Download citation: RISBibTeXText

PMID: 27443345

DOI: 10.1186/s12967-016-0981-y


Related references

Significant low prevalence of antibodies reacting with simian virus 40 mimotopes in serum samples from patients affected by inflammatory neurologic diseases, including multiple sclerosis. Plos one 9(11): E110923, 2014

Measles antibodies, anti-proteinase and plasminogen distribution in serum and plasma from patients affected with multiple sclerosis and patients affected with non-neurological diseases. Journal of Clinical Chemistry and Clinical Biochemistry. Zeitschrift für Klinische Chemie und Klinische Biochemie 22(10): 653-659, 1984

Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Multiple Sclerosis 14(2): 188-196, 2008

Examination of eight cases of multiple sclerosis and 56 neurological and non-neurological controls for genomic sequences of measles virus, canine distemper virus, simian virus 5 and rubella virus. Journal of General Virology 70: 2027-2036, 1989

Antibodies to simian virus 5 in patients with multiple sclerosis and other neurological disorders. Journal of the Neurological Sciences 89(2-3): 181-188, 1989

Caspase-1 levels in biological fluids from patients with multiple sclerosis and from patients with other neurological and non-neurological diseases. European Cytokine Network 13(1): 99-103, 2002

Macrophage inflammatory protein-1 alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. Journal of the Neurological Sciences 129(2): 223-227, 1995

Antibodies against different measles antigens and rubella in patients with multiple sclerosis and other neurological diseases. Medical Microbiology and Immunology-3: 231, 1974

Antibodies against different viral antigens in cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. Acta Neurologica Scandinavica 50(2): 183-193, 1974

IL-2 receptor and HLA class II antigens on cerebrospinal fluid cells of patients with multiple sclerosis and other neurological diseases. Clinical and Experimental Immunology 67(3): 581-586, 1987

Circulating IgE, allergy and multiple sclerosis. Serum levels of IgE, other immunoglobulins and complement (C's) in patients with multiple sclerosis in exacerbation and other neurologic diseases. Acta Neurologica Scandinavica 53(1): 39-50, 1976

Measurement of gamma-interferon in sera and CSF in patients with multiple sclerosis and inflammatory neurological diseases. Rinsho Shinkeigaku 30(5): 557-559, 1990

Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases. Journal of Neuroimmunology 230(1-2): 160-163, 2011

Intrathecal synthesis of immunosuppressive acidic protein (IAP) in patients with multiple sclerosis and other inflammatory neurological diseases. Journal of the Neurological Sciences 85(3): 259-266, 1988

Expression of interleukin 2 receptor and class II histocompatibility antigens on lymphocytes of the cerebrospinal fluid in patients with multiple sclerosis and other neurological diseases. Pathologie-Biologie 35(3): 303-306, 1987